Anti-androgens and other hormonal therapies for prostate cancer

Urology

Volumn 54, Issue 6 SUPPL. 1, 1999, Pages 15-18

  Richie, Jerome P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; ANTIESTROGEN; BICALUTAMIDE; CORTICOSTEROID; DIETHYLSTILBESTROL; FLUTAMIDE; HYDROCORTISONE; KETOCONAZOLE; LEUPRORELIN; MEGESTROL ACETATE; PREDNISONE; SURAMIN; TAMOXIFEN;

ATAXIA; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; HOT FLUSH; HUMAN; MALE; NAUSEA; ORCHIECTOMY; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; THROMBOPHLEBITIS;

EID: 0032777144     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00449-5     Document Type: Article

References (25)

1. Kelly W.K., Scher H.I., Mazumbar M., et al. Prostate specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol. 11:1993;607-615.
2. Smith D.C., Dunn R.L., Strawderman M.S., et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 16:1998;1835-1843.
3. Scher H.I., Kelly W.M., Zhang G.Z., et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 91:1999;244-251.
4. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer Canadian randomized trial with palliated endpoints . J Clin Oncol. 14:1996;1756-1764.
5. Anonymous. Maximum androgen blockade in advanced prostate cancer an overview of 22 randomized trials with 3,823 deaths in 5,710 patients . Lancet. 346:1995;265-269.
6. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 339:1998;1036-1042.
7. Crawford E.D., Eisenberger M.A., Mcleod D.G., et al. Controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
8. Kelly W.K., Scher H.I. Prostate specific antigen decline after anti-androgen withdrawal the flutamide withdrawal syndrome . J Urol. 149:1993;607-609.
9. Herrada J., Dieringer P., Logothetis C.J. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol. 155:1998;620-623.
10. Schellhammer P.F., Venner P., Haas G.P., et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol. 157:1997;1731-1735.
11. Scher H.I., Liebertz C., Kelly W.K., et al. Bicalutamide for advanced prostate cancer the natural versus treated history of disease . J Clin Oncol. 15:1997;2928-2938.
12. Joyce R., Fenton M.A., Rode P., et al. High dose bicalutamide for androgen independent prostate cancer the effect of prior hormonal therapy . J Urol. 159:1998;149-153.
13. Osborn J.L., Smith D.C., Trump D.L. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol. 20:1997;308-310.
14. Loprinzi C.L., Michalak J.C., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 331:1994;347-352.
15. Dawson N.A. Treatment of progressive metastatic prostate cancer. Oncology. 7:1993;17-24.
16. Mahler C., Berhelst J., Denis L. Ketaconazole and liazorole in the treatment of advanced prostate cancer. Cancer. 71:1993;1068-1073.
17. Small E.J., Bavon A.D., Fippin L., et al. Ketoconazole retains activity in advanced prostate cancer patients despite flutamide withdrawal. J Urol. 157:1997;1204-1207.
18. Tannock I., Gospodarowiscz M., Meakin W., et al. Treatment of metastatic prostatic cancer with low dose prednisone Evaluation of pain and quality of life as pragmatic indices of response . J Clin Oncol. 7:1989;590-597.
19. Kantoff P.W., Conaway M., Winer E. Hydrocortisone with and without mitozantrone in patients with hormone refractory prostate cancer preliminary results from a prospective randomized cancer and leukemia group B (9182) trial comparing chemotherapy to best supportive care . Proc Am Soc Clin Oncol. 14:1996;1748.
20. Dawson N.A., Cooper M.R., Figg W.D., et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 76:1995;453-462.
21. Bergan R.C., Blagosklonny M., Dawson N.A. Significant activity by high dose tamoxifen in hormone refractory prostate cancer. Proc Am Soc Clin Oncol. 14:1995;A637.
22. Smith D.C., Redman B.G., Flaherty L.E., et al. A phase II trial of oral diethystilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 52:1998;257-260.
23. Oh W.K., Kantoff P.W. Management of hormone refractory prostate cancer current standards and future prospects . J Urol. 160:1998;1220-1229.
24. Small E.J., Vogelzang N.J. Second-line hormonal therapy for advanced prostate cancer a shifting paradigm . J Clin Oncol. 15:1997;382-388.
25. Reese D.M., Small E.J. Secondary hormonal manipulation in hormone refractory prostate cancer. Urol Clin North Am. 26:1999;311-312.